comparison of pet imaging patterns with psma and ar expression in prostate cancer and bladder cancer

Conditions: Prostate Cancer

Summary: patients suffering either from newly diagnosed very high risk locally advanced and/or oligometastatic prostate cancer (cohort a), metastatic castration-resistant prostate cancer (mcrpc, cohort b), newly diagnosed postate cancer with planned radical prostatectomy (cohort c) or primary bladder cancer with planned radical cystectomy (cohort d) as identified by a multidisciplinary team of specialists, will be included. pet imaging patterns using psma- and fdht pet scans will be correlated with prostate-specific membrane antigen and androgen specific receptor expression patterns in prostate cancer and bladder cancer.


Eligibility criteria:
inclusion criteria: cohort a: * age 18-75 years * histologically or cytologically confirmed adenocarcinoma of the prostate with very high risk for the development of metastases (defined as psa ≥20 or gleason score ≥8 or ≥ct3) and/or oligometastatic (t any, n positive, m any or t any, n any, m positive) * eastern cooperative oncology group (ecog) performance status grade 0 or 1 * planned radical prostatectomy * ≤ 5 osseous metastasis * signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation * willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures cohort b - mcrpc: * age ≥ 18 years * histologically or cytologically confirmed prostate adenocarcinoma. * presence of skeletal or nodal metastases according to one of the following criteria: * confirmed pathological fracture related to the disease or * confirmation of distant bone and/or nodal metastases on ct or mri scan or bone scintigraphy. or * positive pathology report of metastatic lesion. * disease progression despite adt as indicated by: * psa increase that is ≥ 2 ng/ml and ≥ 25% above the minimum psa as reached during adt or above the pre-treatment level, if no response was observed and which is confirmed by a second value 1 or more weeks later. or * progression of measurable lymph nodes (short axis ≥ 15 mm) or visceral lesion measurable per recist or * new metastatic lesions appearing on bone scan/imaging * chemical or surgical castration * eastern cooperative oncology group (ecog) performance status 0-2. * signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation * willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures cohort c: * age ≥ 18 years * histologically or cytologically confirmed prostate adenocarcinoma. * planned radical prostatectomy * signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation * willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures cohort d: * age ≥ 18 years * histologically or cytologically confirmed bladder cancer. * planned radical cystectomy * signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to study participation * willingness and ability to comply with scheduled visits, treatment plans, laboratory and radiographic assessments, and other study procedures exclusion criteria: cohort a: * tumour infiltration of the rectum or pelvic wall * visceral metastasis * hiv positive * any contraindication for surgery * any other condition that, in the opinion of the investigator, would impair the patient's ability to comply with study procedures. * any contraindication for performing a pet/mri scan (if applicable) * patient's not eligible for the size of the pet/mri gantry cohort b - mcrpc: * hiv positive * any contraindication for tissue biopsy (if tissue biopsy is planned) * any contraindication for surgery (if surgery is planned) * any other condition that, in the opinion of the investigator, would impair the patient's ability to comply with study procedures. * any contraindication for performing a pet/mri scan (if applicable) * patient's not eligible for the size of the pet/mri gantry cohort c: * any contraindication for surgery * any other condition that, in the opinion of the investigator, would impair the patient's ability to comply with study procedures. * any contraindication for performing a pet/mri scan (if applicable) * patient's not eligible for the size of the pet/mri gantry cohort d: * any contraindication for surgery * any other condition that, in the opinion of the investigator, would impair the patient's ability to comply with study procedures. * any contraindication for performing a pet/mri scan (if applicable) * patient's not eligible for the size of the pet/mri gantry